Wolverine Trading
CRSP icon

Wolverine Trading’s CRISPR Therapeutics CRSP Stock Holding History

Wolverine Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-47,900
Closed -$1.77M – 4907
2025
Q1 		$1.77M Sell
47,900
-9,400
-16% -$398K ﹤0.01% 1720
2024
Q4 		$2.21M Buy
57,300
+17,200
+43% +$812K ﹤0.01% 1871
2024
Q3 		$1.9M Sell
40,100
-8,100
-17% -$411K ﹤0.01% 1734
2024
Q2 		$2.6M Sell
48,200
-7,100
-13% -$411K ﹤0.01% 1413
2024
Q1 		$3.77M Sell
55,300
-6,100
-10% -$437K ﹤0.01% 1182
2023
Q4 		$3.84M Buy
61,400
+22,000
+56% +$1.22M ﹤0.01% 1273
2023
Q3 		$1.79M Hold
39,400
– – ﹤0.01% 1666
2023
Q2 		$2.25M Buy
39,400
+16,300
+71% +$925K ﹤0.01% 1414
2023
Q1 		$1.02M Buy
23,100
+1,600
+7% +$77.7K ﹤0.01% 1878
2022
Q4 		$874K Sell
21,500
-5,700
-21% -$302K ﹤0.01% 1941
2022
Q3 		$1.75M Sell
27,200
-17,200
-39% -$1.25M ﹤0.01% 1511
2022
Q2 		$2.8M Buy
44,400
+300
+0.7% +$17.6K ﹤0.01% 1143
2022
Q1 		$2.83M Sell
44,100
-31,200
-41% -$1.96M ﹤0.01% 1464
2021
Q4 		$5.94M Sell
75,300
-4,200
-5% -$367K 0.01% 1037
2021
Q3 		$8.76M Sell
79,500
-16,400
-17% -$2.06M 0.01% 896
2021
Q2 		$14.4M Buy
95,900
+6,500
+7% +$791K 0.02% 543
2021
Q1 		$10.3M Buy
89,400
+27,500
+44% +$4.15M 0.02% 679
2020
Q4 		$10M Buy
61,900
+33,200
+116% +$3.92M 0.02% 669
2020
Q3 		$2.44M Sell
28,700
-4,900
-15% -$435K 0.01% 1334
2020
Q2 		$2.52M Buy
33,600
+7,100
+27% +$415K 0.01% 1240
2020
Q1 		$1.17M Buy
26,500
+6,400
+32% +$330K ﹤0.01% 1776
2019
Q4 		$1.24M Sell
20,100
-900
-4% -$49.1K ﹤0.01% 2210
2019
Q3 		$890K Sell
21,000
-7,900
-27% -$377K ﹤0.01% 2081
2019
Q2 		$1.36M Buy
28,900
+5,300
+22% +$212K ﹤0.01% 1793
2019
Q1 		$843K Buy
23,600
+6,200
+36% +$214K ﹤0.01% 2251
2018
Q4 		$465K Sell
17,400
-8,200
-32% -$285K ﹤0.01% 2708
2018
Q3 		$1.14M Buy
+25,600
New +$1.34M ﹤0.01% 2208

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wolverine Trading's CRSP Position: Q2 2025 in Review

Wolverine Trading sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 21,081 shares — an estimated $780K sold.

Wolverine Trading first reported a position in CRSP in Q3 2018 and held it in 23 quarters. The position peaked at $7.5M in Q2 2021. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Wolverine Trading reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Wolverine Trading sold 21,081 CRISPR Therapeutics shares in Q2 2025, an estimated $780K.
  • Wolverine Trading first reported a position in CRISPR Therapeutics in Q3 2018 and held it in 23 quarters.
  • Wolverine Trading's CRISPR Therapeutics position peaked at $7.5M in Q2 2021.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Wolverine Trading's 13F filing for Q2 2025, filed 18 Aug 2025.